The following items correct errors regarding information not originally supplied to MIT Tech Talk:
In an article headlined "Dopamine imaging agent developed" that appeared in the issue of June 5, 1996, the patent application information for technepine and the contributions of Drs. P.C. Meltzer and P. Blundell of Organix Inc., of Woburn were incompletely stated. Seeking a patent for technepine are Organix (40 percent), Harvard University (40 percent) and MIT (20 percent). The unlabelled material was synthesized at Organix using methodology similar but not identical to that developed at MIT. The research by Drs. Meltzer and Blundell was funded by a grant from the National Institute on Neurological Diseases and Stroke to Organix (the principal investigator was Dr. Meltzer).
In a July 24 article headlined "MIT-based program to aid women and minorities," the name of Professor Herman Feshbach, MIT professor of physics emeritus and Institute Professor emeritus, was not included in the list of Advisory Board members.
A version of this article appeared in MIT Tech Talk on August 28, 1996.